The GLP-1 receptor agonist lixisenatide has received US FDA approval for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. Approval was based on 11 clinical trials that evaluated more than 11,000 patients, including a cardiovascular outcomes trial, ELIXA, that showed no increase in adverse cardiovascular events. Efficacy studies […]
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Cardiometabolic Health Congress
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2024, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
